You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

 

Online download statistics by month:

Online download statistics by month: February 2022 to March 2026

AbstractFullPdf
Feb 2022402406172
Mar 2022705711451
Apr 2022274279133
May 202220020697
Jun 2022213218110
Jul 202220721689
Aug 202225926497
Sep 2022249249110
Oct 2022267272144
Nov 2022215217109
Dec 2022192193103
Jan 2023192195102
Feb 202318718895
Mar 2023163169100
Apr 202312412473
May 202314115174
Jun 202315715868
Jul 202312312375
Aug 202313013482
Sep 202313713778
Oct 202314715085
Nov 202313013091
Dec 202313913994
Jan 202412312483
Feb 202413613796
Mar 2024186186166
Apr 2024197200156
May 2024179184135
Jun 2024168168142
Jul 2024202206106
Aug 202418518486
Sep 2024202203103
Oct 202417217299
Nov 2024206207136
Dec 202417818294
Jan 202514414697
Feb 2025185187119
Mar 2025195196145
Apr 2025209210135
May 2025154154132
Jun 202511311466
Jul 2025320
Aug 2025110
Mar 2026220
Total809381944728